IOVA
Iovance Biotherapeutics Inc
11.00$
+1.9%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 96.7% | 98.4% | 98.6% | 96.1% | 98.9% | 91.8% | 82.8% | 65.3% | 72.2% | 39.4% | 50.2% | 48.5% | |
| 96.6% | 98.2% | 96.8% | 93.6% | 17.1% | 4.1% | 8.8% | 10.1% | 34.9% | 14.7% | 12.7% | 17.9% | |
| 96.6% | 98.2% | 96.8% | 93.6% | 97.4% | 89.1% | 81.9% | 64.9% | 71.1% | 35.9% | 35.6% | 32.5% | |
| – | – | – | – | – | – | – | – | 0.0% | 0.0% | 7.6% | 9.0% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | 0.0% | 1.3% | 5.7% | 5.7% | |
| 3.3% | 1.6% | 1.4% | 1.6% | 0.6% | 2.5% | 7.7% | 13.0% | 26.8% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | 29.4% | 31.0% | 30.6% | |
| 3.6% | 1.5% | 2.9% | 6.4% | 3.0% | 13.3% | 14.6% | 20.0% | 24.8% | 25.1% | 22.0% | 23.5% | |
| 3.6% | 1.5% | 2.9% | 6.4% | 3.0% | 11.3% | 7.1% | 11.5% | 13.8% | 14.1% | 13.4% | 15.2% | |
| – | – | – | – | – | 2.1% | 0.8% | 0.7% | 1.9% | 1.0% | 1.4% | 0.4% | |
| 2.7% | 0.9% | 0.5% | 0.8% | 0.6% | 4.5% | 1.8% | 3.5% | 4.0% | 4.2% | 3.0% | 2.4% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | 0.1% | 0.2% | 0.1% | 0.1% | – | |
| 96.4% | 98.5% | 97.1% | 93.6% | 97.0% | 86.7% | 85.4% | 80.0% | 75.2% | 74.9% | 78.0% | 76.5% | |
| -164.6% | -98.6% | -91.4% | -160.4% | -77.5% | -165.6% | -108.0% | -150.8% | -236.2% | -257.9% | -261.9% | -303.9% | |
| 53.7% | 42.0% | 32.2% | 42.0% | 20.2% | 36.1% | 18.0% | 19.7% | 24.0% | 30.1% | 31.8% | 39.1% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.